Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1

References

• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–289.
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–1582.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol. 2004;22:769–773.
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. Ann Oncol. 2017;28:400–407.
   PubMed Web of Science ®Google Scholar
• Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66:337–350.
   PubMed Web of Science ®Google Scholar
• Woopen H, Richter R, Chekerov R, et al. The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). Gynecol Oncol. 2015;138:735–740.
   PubMed Web of Science ®Google Scholar
• Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70:2536–2551.
   PubMedGoogle Scholar
• Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol. 2017;70:2552–2565.
   PubMedGoogle Scholar
• Loar RW, Noel CV, Tunuguntla H, et al. State of the art review: chemotherapy-induced cardiotoxicity in children. Congenit Heart Dis. 2018;13:5–15.
   PubMed Web of Science ®Google Scholar
• Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–2801.
   PubMed Web of Science ®Google Scholar
• Naaktgeboren WR, Linschoten M, de Graeff A, et al. Long-term cardiovascular health in adult cancer survivors. Maturitas. 2017;105:37–45.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. J Clin Oncol. 2012;30:3657–3664.
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Ross JD. Late cardiotoxicity in aging adult survivors of childhood cancer. Prog Pediatr Cardiol. 2014;36:19–26.
   PubMedGoogle Scholar
• Magdy T, Burmeister BT, Burridge PW. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: what is missing? Pharmacol Ther. 2016;168:113–125.
   PubMed Web of Science ®Google Scholar
• Chang VY, Wang JJ. Pharmacogenetics of chemotherapy-induced cardiotoxicity. Curr Oncol Rep. 2018;20:52.
   PubMed Web of Science ®Google Scholar
• Aminkeng F, Ross CJ, Rassekh SR, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82:683–695.
   PubMed Web of Science ®Google Scholar
• Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102–1111.
   PubMed Web of Science ®Google Scholar
• Cautela J, Lalevee N, Ammar C, et al. Management and research in cancer treatment-related cardiovascular toxicity: challenges and perspectives. Int J Cardiol. 2016;224:366–375.
   PubMed Web of Science ®Google Scholar
• Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–1093.
   PubMed Web of Science ®Google Scholar
• Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104:971–977.
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1–01). J Clin Oncol. 2014;32:2159–2165.
   PubMed Web of Science ®Google Scholar
• Rushton M, Johnson C, Dent S. Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population. Curr Oncol. 2017;24:176–180.
   PubMed Web of Science ®Google Scholar
• Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293–1305.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Abdel-Qadir H, Fischer HD, et al. Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol. 2016;34:2239–2246.
   PubMed Web of Science ®Google Scholar
• Azim H, Azim HA Jr., Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev. 2009;35:633–638.
   PubMed Web of Science ®Google Scholar
• Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679–686.
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–2019.
   PubMed Web of Science ®Google Scholar
• Qi WX, Fu S, Zhang Q, et al. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups. Clin Drug Investig. 2014;34:681–690.
   PubMed Web of Science ®Google Scholar
• Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail. 2011;13:1–10.
   PubMed Web of Science ®Google Scholar
• Clark RA, Berry NM, Chowdhury MH, et al. Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis. Intern Med J. 2016;46:1297–1306.
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.
   PubMed Web of Science ®Google Scholar
• de Almeida DVP, Gomes JR, Haddad FJ, et al. Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy. J Immunother. 2018; 41:329–331.
   PubMed Web of Science ®Google Scholar
• Polk A, Vaage-Nilsen M, Vistisen K, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974–984.
   PubMed Web of Science ®Google Scholar
• Polk A, Vistisen K, Vaage-Nilsen M, et al. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47.
   PubMed Web of Science ®Google Scholar
• Rawal G, Yadav S, Kumar R. Paclitaxel induced acute ST elevation myocardial infarction: a rare case report. J Clin Diagn Res. 2016;10:Xd01–xd02.
   PubMed Web of Science ®Google Scholar
• Shah K, Gupta S, Ghosh J, et al. Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature. J Cancer Res Ther. 2012;8:442–444.
   PubMed Web of Science ®Google Scholar
• Di Lisi D, Madonna R, Zito C, et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. Int J Cardiol. 2017;227:11–17.
   PubMed Web of Science ®Google Scholar
• Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66:1160–1178.
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788–1795.
   PubMed Web of Science ®Google Scholar
• Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12:409–425.
   PubMed Web of Science ®Google Scholar
• Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol. 2016;32:852–862.
   PubMed Web of Science ®Google Scholar
• Aghel N, Lipton JH, Atenafu EG, et al. Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up. Clin Lymphoma Myeloma Leuk. 2017;17:870–878.e871.
   PubMed Web of Science ®Google Scholar
• Barni S, Labianca R, Agnelli G, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179.
   PubMed Web of Science ®Google Scholar
• Stewart MH, Jahangir E, Polin NM. Valvular heart disease in cancer patients: etiology, diagnosis, and management. Curr Treat Options Cardiovasc Med. 2017;19:53.
   PubMedGoogle Scholar
• Allen J, Thomson JD, Lewis IJ, et al. Mitral regurgitation after anthracycline treatment for childhood malignancy. Heart. 2001;85:430–432.
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878–1886.
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007–1017.
   PubMed Web of Science ®Google Scholar
• Murbraech K, Wethal T, Smeland KB, et al. Valvular dysfunction in lymphoma survivors treated with autologous stem cell transplantation: a national cross-sectional study. JACC Cardiovasc Imaging. 2016;9:230–239.
   PubMed Web of Science ®Google Scholar
• Mulrooney DA, Armstrong GT, Huang S, et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: a cross-sectional study. Ann Intern Med. 2016;164:93–101.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015;38:129–152.
   PubMed Web of Science ®Google Scholar
• Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep. 2016;18:52.
   PubMed Web of Science ®Google Scholar
• Alexandre J, Moslehi JJ, Bersell KR, et al. Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018;189:89–103.
   PubMed Web of Science ®Google Scholar
• Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009;11:1579–1586.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9:1704–1712.
   PubMed Web of Science ®Google Scholar
• Clasen SC, Ky B, O’Quinn R, et al. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol. 2017;8:970–979.
   PubMed Web of Science ®Google Scholar
• Oun R, Rowan E. Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node? Eur J Pharmacol. 2017;811:125–128.
   PubMed Web of Science ®Google Scholar
• Menna P, Salvatorelli E, Minotti G. Cancer drugs and QT prolongation: weighing risk against benefit. Expert Opin Drug Saf. 2017;16:1099–1102.
   PubMed Web of Science ®Google Scholar
• Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One. 2012;7:e30353.
   PubMed Web of Science ®Google Scholar
• Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112:296–305.
   PubMed Web of Science ®Google Scholar
• Bronte E, Bronte G, Novo G, et al. What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget. 2015;6:35589–35601.
   PubMedGoogle Scholar
• Schiefer M, Hendriks LEL, Dinh T, et al. Current perspective: osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Eur J Cancer. 2018;91:92–98.
   PubMed Web of Science ®Google Scholar
• Porta-Sanchez A, Gilbert C, Spears D, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc. 2017;6.
   Web of Science ®Google Scholar
• Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609–3615.
   PubMed Web of Science ®Google Scholar
• Khan Q, Ismail M, Khan S. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study. BMC Pharmacol Toxicol. 2017;18:75.
   PubMed Web of Science ®Google Scholar
• Barni S, Petrelli F, Cabiddu M. Cardiotoxicity of antiemetic drugs in oncology: an overview of the current state of the art. Crit Rev Oncol Hematol. 2016;102:125–134.
   PubMed Web of Science ®Google Scholar
• Arora N, Gupta A, Singh PP. Biological agents in gastrointestinal cancers: adverse effects and their management. J Gastrointest Oncol. 2017;8:485–498.
   PubMed Web of Science ®Google Scholar
• Mushtaq A, Kapoor V, Latif A, et al. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol. 2018;125:1–11.
   PubMed Web of Science ®Google Scholar
• Abi Aad S, Pierce M, Barmaimon G, et al. Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge. Crit Rev Oncol Hematol. 2015;93:28–35.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–2164.
   PubMed Web of Science ®Google Scholar
• Gavazzoni M, Vizzardi E, Gorga E, et al. Mechanism of cardiovascular toxicity by proteasome inhibitors: new paradigm derived from clinical and pre-clinical evidence. Eur J Pharmacol. 2018;828:80–88.
   PubMed Web of Science ®Google Scholar
• Brinda BJ, Viganego F, Vo T, et al. Anti-VEGF-induced hypertension: a review of pathophysiology and treatment options. Curr Treat Options Cardiovasc Med. 2016;18:33.
   PubMedGoogle Scholar
• Hall PS, Harshman LC, Srinivas S, et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1:72–78.
   PubMed Web of Science ®Google Scholar
• Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–160.
   PubMed Web of Science ®Google Scholar
• Small HY, Montezano AC, Rios FJ, et al. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol. 2014;30:534–543.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210–4218.
   PubMed Web of Science ®Google Scholar
• Liu B, Ding F, Liu Y, et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget. 2016;7:67661–67673.
   PubMedGoogle Scholar
• Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016;126:3207–3218.
   PubMed Web of Science ®Google Scholar
• Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128–2137.
   PubMed Web of Science ®Google Scholar
• Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90:1060–1064.
   PubMed Web of Science ®Google Scholar
• Gore L, Kearns PR, de Martino ML, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol. 2018;36:1330–1338.
   PubMed Web of Science ®Google Scholar
• Westerink NL, Nuver J, Lefrandt JD, et al. Cancer treatment induced metabolic syndrome: improving outcome with lifestyle. Crit Rev Oncol Hematol. 2016;108:128–136.
   PubMed Web of Science ®Google Scholar
• Chueh HW, Yoo JH. Metabolic syndrome induced by anticancer treatment in childhood cancer survivors. Ann Pediatr Endocrinol Metab. 2017;22:82–89.
   PubMed Web of Science ®Google Scholar
• Rosen GP, Nguyen HT, Shaibi GQ. Metabolic syndrome in pediatric cancer survivors: a mechanistic review. Pediatr Blood Cancer. 2013;60:1922–1928.
   PubMed Web of Science ®Google Scholar
• Kate A, Kadambari D. Incidence of metabolic syndrome in breast cancer survivors on adjuvant hormonal therapy. J Pharmacol Pharmacother. 2016;7:28–30.
   PubMed Web of Science ®Google Scholar
• Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc. 2014;3:e000665.
   PubMed Web of Science ®Google Scholar
• Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta. 2016;1863:1916–1925.
   PubMed Web of Science ®Google Scholar
• Rayson D, Richel D, Chia S, et al. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol. 2008;19:1530–1539.
   PubMed Web of Science ®Google Scholar
• Rochette L, Guenancia C, Gudjoncik A, et al. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci. 2015;36:326–348.
   PubMed Web of Science ®Google Scholar
• Maurea N, Coppola C, Piscopo G, et al. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1):e19–e26. Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection.
   PubMedGoogle Scholar
• Milano GA, Serres E, Ferrero JM, et al. Trastuzumab-induced cardiotoxicity: is it a personalized risk? Curr Drug Targets. 2014;15:1200–1204.
   PubMed Web of Science ®Google Scholar
• Kerkela R, Woulfe KC, Durand JB, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009;2:15–25.
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–344.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755.
   PubMed Web of Science ®Google Scholar
• Cheng F, Loscalzo J. Autoimmune cardiotoxicity of cancer immunotherapy. Trends Immunol. 2017;38:77–78.
   PubMed Web of Science ®Google Scholar
• Horacek JM, Pudil R, Jebavy L, et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol. 2007;29:309–313.
   PubMedGoogle Scholar
• Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47–58.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–1988.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94:525–533.
   PubMed Web of Science ®Google Scholar
• Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006;5:791–809.
   PubMed Web of Science ®Google Scholar
• Layoun ME, Wickramasinghe CD, Peralta MV, et al. Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management. Curr Oncol Rep. 2016;18:35.
   PubMed Web of Science ®Google Scholar
• Depetris I, Marino D, Bonzano A, et al. Fluoropyrimidine-induced cardiotoxicity. Crit Rev Oncol Hematol. 2018;124:1–10.
   PubMed Web of Science ®Google Scholar
• Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Ann Oncol. 2014;25:117–121.
   PubMed Web of Science ®Google Scholar
• Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer. 2008;44:2204–2211.
   PubMed Web of Science ®Google Scholar
• Yh S, Tornvall P, Tornerud M, et al. Capecitabine caused cardiogenic shock through induction of global Takotsubo syndrome. Cardiovasc Revasc Med. 2013;14:57–61.
   PubMedGoogle Scholar
• Basselin C, Fontanges T, Descotes J, et al. 5-Fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy. 2011;31:226.
   PubMed Web of Science ®Google Scholar
• Goldberg MA, Antin JH, Guinan EC, et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68:1114–1118.
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758–763.
   PubMed Web of Science ®Google Scholar
• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–2247.
   PubMed Web of Science ®Google Scholar
• Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9:1215–1223.
   PubMed Web of Science ®Google Scholar
• Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118:31–36.
   PubMed Web of Science ®Google Scholar
• Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160:2021–2024.
   PubMed Web of Science ®Google Scholar
• Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18:1725–1732.
   PubMed Web of Science ®Google Scholar
• Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993; 15: 117–130.
   PubMedGoogle Scholar
• Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993;20:1–15.
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995;13:2688–2699.
   PubMed Web of Science ®Google Scholar
• Tomonari M, To H, Nishida M, et al. Mechanism of the cardioprotective effects of docetaxel pre-administration against adriamycin-induced cardiotoxicity. J Pharmacol Sci. 2011;115:336–345.
   PubMed Web of Science ®Google Scholar
• Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2013;8:82–95.
   PubMed Web of Science ®Google Scholar
• Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34:1514–1521.
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf. 2006;29:209–230.
   PubMed Web of Science ®Google Scholar
• Airey CL, Dodwell DJ, Joffe JK, et al. Etoposide-related myocardial infarction. Clin Oncol (R Coll Radiol). 1995;7:135.
   PubMedGoogle Scholar
• Escoto H, Ringewald J, Kalpatthi R. Etoposide-related cardiotoxicity in a child with haemophagocytic lymphohistiocytosis. Cardiol Young. 2010;20:105–107.
   PubMed Web of Science ®Google Scholar
• Ozkan HA, Bal C, Gulbas Z. Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide. Transfus Apher Sci. 2014;50:46–52.
   PubMed Web of Science ®Google Scholar
• Rivera F, Galan M, Tabernero J, et al. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys. 2009;75:1430–1436.
   PubMed Web of Science ®Google Scholar
• Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):58–66.
   PubMedGoogle Scholar
• Pereg D, Lishner M. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur Heart J. 2008;29:2325–2326.
   PubMed Web of Science ®Google Scholar
• Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin. 2013;9: 233–242. x.
   PubMed Web of Science ®Google Scholar
• Tarantini L, Gori S, Faggiano P, et al. Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol. 2012;23:3058–3063.
   PubMed Web of Science ®Google Scholar
• Chen J, Long JB, Hurria A, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60:2504–2512.
   PubMed Web of Science ®Google Scholar
• Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc. 2017;6:e006278.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98–106.
   PubMed Web of Science ®Google Scholar
• Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. 2018;96:21–33.
   PubMed Web of Science ®Google Scholar
• Laubli H, Balmelli C, Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–225.
   PubMed Web of Science ®Google Scholar
• Tadokoro T, Keshino E, Makiyama A, et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail. 2016;9.
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498–509.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2:e000247.
   PubMed Web of Science ®Google Scholar
• Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085–2087.
   PubMed Web of Science ®Google Scholar
• Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755–1764.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5:95.
   PubMed Web of Science ®Google Scholar